Cabaletta Bio

CABAPhase 3

Philadelphia, United StatesFounded 2017cabalettabio.com

Cabaletta Bio is focused on developing engineered T cell therapies to potentially cure patients with autoimmune diseases by resetting the immune system. The company leverages its proprietary Cabaletta Approach to B cell Ablation (CABA) platform, which includes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach. Its lead candidate, rese-cel, is being evaluated in five RESET Phase 1/2 trials across rheumatology, dermatology, and neurology indications. Cabaletta aims to build a leading, fully integrated cell therapy company focused on transforming the treatment paradigm for autoimmune diseases.

Market Cap

$283.0M

Founded

2017

Focus

Cell & Gene Therapy

CABA · Stock Price

USD 2.94+0.82 (+38.68%)

Historical price data

AI Company Overview

Technology Platform

The Cabaletta Approach to B cell Ablation (CABA) platform, featuring Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) designed to transiently eliminate B cells to reset the immune system, and Chimeric AutoAntibody Receptor T cells (CAAR T) for targeted B cell depletion.

Pipeline Snapshot

7 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
CABA-201 following preconditioning with fludarabine and cyclophosphamide	Idiopathic Inflammatory Myopathy	Phase 2/3
CABA-201	Systemic Sclerosis	Phase 1/2
CABA-201	Generalized Myasthenia Gravis (gMG)	Phase 1/2
CABA-201	Relapsing Multiple Sclerosis (RMS)	Phase 1/2
DSG3-CAART + CABA-201	Pemphigus Vulgaris	Phase 1/2

Funding History

Total raised: $200M

Series B$75MAdage Capital ManagementJan 15, 2020

IPO$75MUndisclosedOct 24, 2019

Series A$50MAdage Capital ManagementOct 15, 2018

Opportunities

Cabaletta has a significant opportunity to establish a new treatment paradigm for autoimmune diseases with a one-time, potentially curative therapy.

Success in its ongoing trials could unlock a multi-billion dollar market across rheumatology, dermatology, and neurology.

The platform approach allows for rapid expansion into additional autoimmune indications.

Risk Factors

Key risks include clinical trial failure, safety concerns in autoimmune patients, complex manufacturing and logistics, uncertain regulatory pathways for novel cell therapies, high future capital needs, and emerging competition from larger biopharma companies entering the space.

Competitive Landscape

Cabaletta is a pioneer in developing CD19-CAR T for autoimmunity, competing with companies like Kyverna Therapeutics and academic centers. Its differentiation lies in its focused strategy, fully human CAR construct, and broad multi-indication pipeline. It faces potential future competition from large CAR T players like Novartis and Bristol Myers Squibb.